Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mara Silvia Monzini"'
Autor:
Margaret Macro, Andrew Ar Belch, Antoine Tinel, Nathalie Meuleman, Jean Yves Mary, Christian Rose, Paula Rodriguez-Otero, Philippe Moreau, Wenming Chen, Michel Attal, Marie Lorraine Chretien, William Renwick, Kihyun Kim, Meletios A. Dimopoulos, Eileen M Boyle, Xavier Leleu, Michael Sturniolo, Thierry Facon, Heinz Ludwig, Mara Silvia Monzini, Vanessa Houck, Elena Zamagni, Adrian Tempescul, Salomon Manier, Cyrille Hulin, Shien Guo, Mohamad Mohty, Bruno M. Costa
Publikováno v:
Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2019, ⟨10.1038/s41375-019-0539-0⟩
Leukemia, 2019, ⟨10.1038/s41375-019-0539-0⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2019, ⟨10.1038/s41375-019-0539-0⟩
Leukemia, 2019, ⟨10.1038/s41375-019-0539-0⟩
Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment. Patients from the large, phase 3 FIRST trial in newly diagnosed multiple myeloma (NDMM) were retrospectively investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a562b6d51f21d0a472d0997eba185f4f
https://pubmed.ncbi.nlm.nih.gov/31980732
https://pubmed.ncbi.nlm.nih.gov/31980732
Autor:
Christian Jacques, Antonio Palumbo, Lars Sternas, Pieter Sonneveld, Xin Yu, Mohamed H. Zaki, Stephen Schey, Ramesh Amatya, Mara Silvia Monzini, Kevin W. Song, Philippe Moreau, Jesús F. San Miguel, Katja Weisel, Meletios A. Dimopoulos, Andrew R. Belch
Publikováno v:
Haematologica, 100(2), E63-E67. Ferrata Storti Foundation
Song, K W, Dimopoulos, M A, Weisel, K C, Moreau, P, Palumbo, A, Belch, A, Schey, S, Sonneveld, P, Sternas, L, Yu, X, Amatya, R, Monzini, M S, Zaki, M, Jacques, C & Miguel, J S 2015, ' Health-RELATED quality of life from the MM-003 trial of pomalidomide plus LOW-Dose dexamethasone VERSUS HIGH-DOSE dexamethasone in relapsed and/or refractory multiple myeloma ', Haematologica, vol. 100, no. 2, pp. 63-67 . https://doi.org/10.3324/haematol.2014.112557
Song, K W, Dimopoulos, M A, Weisel, K C, Moreau, P, Palumbo, A, Belch, A, Schey, S, Sonneveld, P, Sternas, L, Yu, X, Amatya, R, Monzini, M S, Zaki, M, Jacques, C & Miguel, J S 2015, ' Health-RELATED quality of life from the MM-003 trial of pomalidomide plus LOW-Dose dexamethasone VERSUS HIGH-DOSE dexamethasone in relapsed and/or refractory multiple myeloma ', Haematologica, vol. 100, no. 2, pp. 63-67 . https://doi.org/10.3324/haematol.2014.112557
Advances in treatments for multiple myeloma (MM) have resulted in improved survival. However, patients who have become refractory to novel agents have a poor prognosis, with a median overall survival (OS) of nine months, or as low as three months in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3be0af1016de8cb23bc820e4b19e7a5
https://europepmc.org/articles/PMC4803120/
https://europepmc.org/articles/PMC4803120/
Autor:
Saad Z. Usmani, X. Henry Hu, Andy Surinach, Yasir Nagarwala, Mara Silvia Monzini, Steven R. Arikian, Frank A. Corvino, Mohamad A. Hussein, Dejan Milentijevic, Gary Binder
Publikováno v:
Web of Science
Introduction: As clinical evidence has mounted in support of novel agents and longer treatment (Tx) durations for patients (pts) with newly diagnosed multiple myeloma (NDMM), questions have arisen regarding the economic impact of extending time to pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db2ee7fae598c233635160280dd2381d
https://doi.org/10.1182/blood.v124.21.2656.2656
https://doi.org/10.1182/blood.v124.21.2656.2656
Publikováno v:
Blood. 124:1318-1318
Introduction: Multiple myeloma (MM) is an incurable hematologic malignancy. Due to the introduction of newer MM treatments, patient survival has increased and outcomes have improved over the last 10 years, but not without questions arising regarding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::884e9bfcaf34200dc8cec128ab542519
https://doi.org/10.1182/blood.v124.21.1318.1318
https://doi.org/10.1182/blood.v124.21.1318.1318
Autor:
Dan T. Vogl, Thierry Facon, Michel Delforge, Albert Oriol, Robin Foà, Jamie Cavenagh, Annette Ervin-Haynes, Mara Silvia Monzini, Shien Guo, Philippe Rodon, Bertrand Arnulf, Kevin W. Song, Jason Van Oostendorp, Cyrille Hulin, Katja Weisel, Meletios A. Dimopoulos
Publikováno v:
Blood. 124:1326-1326
Introduction: Multiple myeloma (MM) is an incurable hematologic condition that is associated with high Tx costs. Resource consumption is driven by hospitalization and medical utilization, which is highest during periods of uncontrolled disease, such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec44bcbbc2d81538782a4de0614de935
https://doi.org/10.1182/blood.v124.21.1326.1326
https://doi.org/10.1182/blood.v124.21.1326.1326
Autor:
Mara Silvia Monzini, Philippe Moreau, Albert Oriol, Christian Jacques, Nizar J. Bahlis, Jesús F. San Miguel, Katja Weisel, Mohamed H. Zaki, Stefan Knop, Andrew Spencer, Anne Banos, Kevin W. Song, Michel Delforge, Christoph Renner, Ramesh Amatya, Hartmut Goldschmidt, Lionel Karlin, Lars Sternas, Meletios A. Dimopoulos, X Yu
Publikováno v:
Blood. 122:2939-2939
Background Pronounced symptoms, poor prognosis, and therapy exhaustion each affect HRQoL in RRMM patients. The MM-003, randomized, multicenter, open-label phase 3 trial reported that POM + LoDEX significantly extended median progression-free and over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2c9be3abb1335969986112b698aa96f
https://doi.org/10.1182/blood.v122.21.2939.2939
https://doi.org/10.1182/blood.v122.21.2939.2939